Insider trading

Period: 120 months Stock: TECH Plan: Not stated × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

110 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

110 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

110 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

110 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
110 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
110 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

110 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
8 Dec 2022
Furlow Brenda S. SVP - GENERAL COUNSEL
Sold, plan not stated
$611.81K 7,450 at 82.12
22.2%
7 Dec 2022
Furlow Brenda S. SVP - GENERAL COUNSEL
Sold, plan not stated
$65.61K 800 at 82.01
3.0%
11 Aug 2022
HIGGINS JOHN L Director
Sold, plan not stated 2×
$197.32K 512 at 385.40
8.5%
10 Aug 2022
HIGGINS JOHN L Director
Sold, plan not stated 3×
$751.19K 1,992 at 377.11
24.9%
8 Jun 2022
HIGGINS JOHN L Director
Sold, plan not stated
$219.65K 600 at 366.09
11.5%
7 Jun 2022
Kummeth Charles R. CHIEF EXECUTIVE OFFICER
Sold, plan not stated
$1.86M 5,104 at 365.00
2.5%
7 Jun 2022
HIGGINS JOHN L Director
Sold, plan not stated
$364.31K 1,000 at 364.31
17.8%
10 May 2022
Bought
$105.77K 300 at 352.55
3.1%
First buy on file
19 Nov 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated 2×
$252.69K 500 at 505.38
100%
Sold half or more
12 Nov 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated 10×
$13.69M 27,159 at 504.00
95.4%
Sold half or more
2 Nov 2021
Hippel James Chief Financial Officer
Sold, plan not stated
$105.02K 200 at 525.10
1.8%
1 Nov 2021
Hippel James Chief Financial Officer
Sold, plan not stated 4×
$4.64M 8,822 at 526.52
45.1%
29 Oct 2021
Hippel James Chief Financial Officer
Sold, plan not stated
$347.70K 662 at 525.23
5.8%
28 Oct 2021
Hippel James Chief Financial Officer
Sold, plan not stated
$52.52K 100 at 525.18
0.9%
22 Sep 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$434.87K 822 at 529.04
100%
Sold half or more
7 Sep 2021
STEER RANDOLPH C Director
Sold, plan not stated 3×
$4.08M 8,000 at 509.98
61.0%
Sold half or more
2 Sep 2021
Hippel James Chief Financial Officer
Sold, plan not stated 2×
$5.07M 10,000 at 507.22
48.0%
2 Sep 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 2×
$3.50M 6,871 at 509.94
47.4%
31 Aug 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 3×
$2.53M 5,000 at 505.66
39.6%
31 Aug 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated
$773.73K 1,538 at 503.07
53.9%
Sold half or more
23 Aug 2021
Sold, plan not stated 6×
$1.94M 4,000 at 485.55
29.4%
23 Aug 2021
Nusse Roeland Director
Sold, plan not stated
$1.93M 4,000 at 481.52
37.2%
19 Aug 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 3×
$1.68M 3,538 at 473.95
31.7%
9 Aug 2021
Hippel James Chief Financial Officer
Sold, plan not stated 8×
$4.79M 10,000 at 478.90
48.0%
12 Jul 2021
Hippel James Chief Financial Officer
Sold, plan not stated 13×
$4.57M 10,000 at 456.67
52.3%
Sold half or more
18 Jun 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated 2×
$1.31M 2,909 at 449.23
1.8%
17 Jun 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated 4×
$4.31M 9,589 at 449.81
5.7%
14 Jun 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated 2×
$3.36M 7,481 at 449.15
4.3%
9 Jun 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$351.16K 811 at 433.00
100%
Sold half or more
7 Jun 2021
Hippel James Chief Financial Officer
Sold, plan not stated 6×
$4.19M 9,942 at 421.93
52.1%
Sold half or more
25 May 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$358.28K 845 at 424.00
51.0%
Sold half or more
12 Feb 2021
Hippel James Chief Financial Officer
Sold, plan not stated 2×
$4.00M 10,000 at 400.39
52.3%
Sold half or more
12 Feb 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 2×
$3.99M 10,000 at 398.64
62.0%
Sold half or more
8 Feb 2021
Nusse Roeland Director
Sold, plan not stated
$2.31M 6,000 at 385.08
47.0%
5 Feb 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated 7×
$12.54M 32,933 at 380.68
96.2%
Sold half or more
5 Feb 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$319.69K 823 at 388.45
49.3%
15 Jan 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated
$6.88M 20,000 at 344.00
12.0%
11 Jan 2021
Hippel James Chief Financial Officer
Sold, plan not stated 6×
$3.34M 10,000 at 333.63
52.3%
Sold half or more
7 Dec 2020
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated
$1.54M 5,000 at 308.00
2.9%
30 Nov 2020
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 3×
$3.28M 10,857 at 301.94
63.9%
Sold half or more
18 Nov 2020
Sold, plan not stated
$1.52M 5,000 at 303.34
34.2%
11 Nov 2020
Hippel James Chief Financial Officer
Sold, plan not stated 2×
$2.27M 7,391 at 307.05
44.7%
9 Nov 2020
Seth Alpna Director
Sold, plan not stated 2×
$1.54M 5,023 at 306.62
70.1%
Sold half or more
9 Nov 2020
Hippel James Chief Financial Officer
Sold, plan not stated 5×
$1.12M 3,600 at 309.79
28.3%
6 Nov 2020
STEER RANDOLPH C Director
Sold, plan not stated 6×
$3.02M 10,000 at 301.99
66.2%
Sold half or more
6 Nov 2020
HIGGINS JOHN L Director
Sold, plan not stated 3×
$1.50M 5,000 at 300.35
53.1%
Sold half or more
5 Nov 2020
Hippel James Chief Financial Officer
Sold, plan not stated 10×
$2.52M 8,809 at 286.12
49.1%
4 Nov 2020
Hippel James Chief Financial Officer
Sold, plan not stated 4×
$1.95M 7,100 at 274.00
43.7%
9 Jul 2020
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 8×
$2.50M 9,079 at 275.76
67.8%
Sold half or more
7 Jul 2020
Hippel James Chief Financial Officer
Sold, plan not stated 3×
$699.48K 2,577 at 271.43
21.7%
Showing 1–50 of 110. Page 1 of 3 Older →